DelveInsight’s “Dry Eye Disease Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Dry Eye Disease, historical and forecasted epidemiology as well as the Dry Eye Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Dry Eye Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Dry Eye Disease Market Forecast 2034
Some of the key facts of the Dry Eye Disease Market Report:
In 2023, the market for Dry Eye Disease (DED) was largest in the United States among the 7MM, accounting for approximately USD 2.74 billion, with further growth anticipated through 2034.
The total diagnosed prevalence of DED in the 7MM was also highest in the US in 2023, with nearly 22.48 million cases, a number that is expected to rise by 2034. In Japan, approximately 2.34 million males and 8.30 million females were affected by DED in 2023, with projections indicating an increase by 2034.
In the UK, 2023 saw approximately 2.81 million cases of mild, 1.35 million cases of moderate, and 1.96 million cases of severe DED. According to analysis by DelveInsight’s experts, the overall severity-specific cases of DED are expected to rise in the coming years.
The current DED market includes both marketed therapies such as VEVYE (cyclosporine ophthalmic solution), TYRVAYA, EYSUVIS (loteprednol etabonate ophthalmic suspension), CEQUA (cyclosporine ophthalmic solution), off-label therapies, and eye drops. In 2023, the market size across the 7MM was valued at USD 3.76 billion, with expectations for growth driven by the launch of emerging therapies during the forecast period (2024–2034).
In March 2023, Selagine, Inc., a spin-out company from the University of Illinois at Chicago (UIC), announced that it has entered into a research, development, and sublicense agreement with Grifols (Nasdaq: GRFS), a global leader in plasma-derived medicines, for the development and commercialization of immunoglobulin eye drops for dry eye disease.Under the agreement, Selagine will receive an upfront payment and annual collaboration fee. In addition, Grifols has committed to fund the development of immunoglobulin eye drops through FDA approval, which will be managed collaboratively by Grifols and Selagine, including the clinical, manufacturing and regulatory activities required for FDA approval for dry eye disease indication.
In February 2023, Aldeyra Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for topical ocular reproxalap, a first-in-class investigational new drug candidate, for the treatment of the signs and symptoms of dry eye disease. The FDA assigned a Prescription Drug User Fee Act (PDUFA) date of November 23, 2023. The FDA noted that no potential filing review issues have been identified, and that an advisory committee meeting is not currently planned.
In February 2023, Novaliq, announced its plans for filing a Marketing Authorisation Application (MAA) for CyclASol® (ciclosporin ophthalmic solution), a first-of-its-kind anti-inflammatory product for the treatment of dry eye disease (DED) in the European Union. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) determined that CyclASol® is eligible to be reviewed in a centralized procedure to receive a Union Marketing Authorisation for the European Economic Area (EEA).
In January 2023, Bausch + Lomb Corporation and Novaliq GmbH, announced that Ophthalmology, the peer-reviewed journal of the American Academy of Ophthalmology, has published results from the pivotal Phase 3 trial GOBI, which is one of two pivotal Phase 3 trials for NOV03 (perfluorohexyloctane). NOV03 is being investigated to treat the signs and symptoms of dry eye disease (DED) associated with Meibomian gland dysfunction (MGD).In the study, NOV03 was well tolerated with few subjects experiencing ocular adverse events (AEs) (9.6% NOV03 group, 7.5% control group) or treatment-related ocular AEs (6.3% NOV03 group, 3.1% control group).
In August 2022, Alcon and Aerie Pharmaceuticals, Inc. announced the companies have entered into a definitive merger agreement through which Alcon acquired Aerie. The transaction affirmed Alcon’s commitment to the ophthalmic pharmaceutical space and is expected to add broader pharmaceutical R&D capabilities to Alcon’s existing commercial expertise, maximizing the value of its diversified portfolio. Through the transaction, Alcon added the commercial products Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% and Rhopressa® (netarsudil ophthalmic solution) 0.02%, as well as AR-15512, a Phase 3 product candidate for dry eye disease, and a pipeline of several clinical and preclinical ophthalmic pharmaceutical product candidates.
In May 2022, Yuyu Pharmaceutical presented a poster study for YP-P10, its new dry eye syndrome treatment, during the 2022 ARVO (Association for Research in Vision and Ophthalmology) conference. YP-P10 is a new biopharmaceutical using synthetic peptides, aiming to relieve signs and symptoms of dry eye syndrome caused by inflammation by administering the treatment twice a day. According to preclinical trial results unveiled at the conference, Yuyu confirmed that the candidate had an excellent anti-inflammatory mechanism and corneal epithelial cell healing effect compared to existing drugs.
Key Dry Eye Disease Companies: Alcon, Allysta Pharmaceuticals, Aramis Biosciences, BRIM Biotechnology, Dreamhawk Vision Biotech, Inc., HanAll Biopharma, Invirsa, IVIEW Therapeutics, Kowa Company, MC2 Therapeutics, Novaliq, Novaliq GmbH, Noveome, Ocular Therapeutix, Palatin Technologies, Quorum Innovations, Seikagaku Corporation, Seinda Pharmaceutical, Serentrix, Taejoon Pharmaceutical, and others.
Key Dry Eye Disease Therapies: OTX-DED (Ocular Therapeutix), HL036 (tanfanercept) (HanAll Biopharma/Daewoong Pharmaceutical, PL9643 (Palatin Technologies), and others
According to Dana et al. (2020), the overall Dry Eye Disease prevalence was 5.28%, wherein the prevalence among females and males was about 7.78% and 2.96%, respectively, in the US. Besides, the prevalence increased with age from 0.20%, for ages 2–17 years, to 11.66% for individuals aged above 50.
According to a study by Dalton et al. (2020), around 16 million Americans have been diagnosed with Dry Eye Disease, but the actual number of Americans suffering from dry eye symptoms is likely much higher. Some reports indicate that nearly half of all US adults experience dry eye signs and symptoms, and 33% of patients in eye care clinics present with complaints about dry eye.
According to the Association of Optometrists, dry eye is a very common condition in the UK, affecting one in four people in the UK.
The Dry Eye Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Dry Eye Disease pipeline products will significantly revolutionize the Dry Eye Disease market dynamics.
Dry Eye Disease Overview
Dry eye disease (DED), also known as dry eye syndrome or keratoconjunctivitis sicca, is a common condition characterized by insufficient tear production or excessive tear evaporation. This results in inadequate lubrication and hydration of the ocular surface, leading to symptoms such as dryness, redness, swelling, and irritation. Contributing factors to DED include reduced tear production, increased tear evaporation, and imbalances in the components of the tear film, such as the mucus or lipid layers. Persistent dryness can range from mild discomfort to severe inflammation and, in extreme cases, scarring of the cornea. DED can affect one or both eyes and often leads to chronic inflammation.
The hallmark symptom of dry eye disease is a feeling of dryness or grittiness in the eyes. Other common symptoms include a burning or itching sensation, the feeling of a foreign body in the eye, excessive tearing, eye pain, redness, and sensitivity to light. Some individuals may also experience a stringy discharge or notice changes in vision clarity. These symptoms often worsen in environments with low humidity, high temperatures, or dry climates. Prolonged dryness can result in superficial scratches on the corneal surface, and in severe cases, it can lead to more significant damage, including squamous metaplasia and a reduction in goblet cells in the corneal epithelium.
Dry Eye Disease Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Dry Eye Disease Epidemiology Segmentation:
The Dry Eye Disease market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
Total Prevalence of Dry Eye Disease
Prevalent Cases of Dry Eye Disease by severity
Gender-specific Prevalence of Dry Eye Disease
Diagnosed Cases of Episodic and Chronic Dry Eye Disease
Download the report to understand which factors are driving Dry Eye Disease epidemiology trends @ Dry Eye Disease Epidemiology Insights
Dry Eye Disease Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Dry Eye Disease market or expected to get launched during the study period. The analysis covers Dry Eye Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Dry Eye Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Dry Eye Disease Therapies and Key Companies
A197: Aramis Biosciences
AR-15512: Aerie Pharmaceuticals
CLX-OPH-621: Cellix Bio
CyclASol: Novaliq GmbH
GLH8NDE: GL Pharm TechCorporation
HL036: HanAll Biopharma
INV-102: Invirsa
iVIEW 1001: IVIEW Therapeutics
K-161: Kowa Research Institute, Inc.
NOV03: Novaliq GmbH
OTX-DED: Ocular Therapeutix
Qi 401: Quorum Innovations
SER-114: Serentrix
SHJ 002: Dreamhawk Vision Biotech, Inc.
SI-614: Seikagaku Corporation
SY-201: Seinda Pharmaceutical
TJO-083: Taejoon Pharmaceutical Co., Ltd.
And Many More
Dry Eye Disease Therapeutics Analysis
The goal of managing dry eye disease (DED) is to relieve discomfort and protect the cornea—the transparent, front part of the eye—from potential damage. Treatment options for DED vary depending on the severity of the condition and may include medications, surgical interventions, and supportive measures such as eyelid therapy (e.g., warm compresses and eyelid hygiene), the use of special contact lenses, or moisture chamber spectacles.
Treatment selection is largely based on the underlying cause of the dry eye. Artificial tears are typically the first line of treatment, helping to lubricate the eye and alleviate dryness. Wrap-around glasses that fit snugly to the face can help minimize tear evaporation. In some cases, adjusting or discontinuing certain medications may improve symptoms. Medications like cyclosporine (Restasis) or steroid eye drops may be prescribed for more severe cases. Another treatment option is the use of lacrimal plugs, which block the drainage of tears from the eye surface to help retain moisture.
For some patients, wearing contact lenses may become difficult due to discomfort caused by dry eyes. However, a range of therapies, such as MIEBO (perfluorohexyloctane ophthalmic solution), Xiidra (lifitegrast ophthalmic solution), and Tyrvaya nasal spray, have been approved to address both the signs and symptoms of DED.
The DED market is expected to experience significant growth in the near future with the anticipated launch of several promising therapies, including OTX-DED (Ocular Therapeutix), HL036 (tanfanercept) from HanAll Biopharma/Daewoong Pharmaceutical, and PL9643 (Palatin Technologies), among others. These new treatments are expected to offer innovative solutions, improving outcomes for patients with dry eye disease.
Scope of the Dry Eye Disease Market Report
Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Dry Eye Disease Companies: Alcon, Allysta Pharmaceuticals, Aramis Biosciences, BRIM Biotechnology, Dreamhawk Vision Biotech, Inc., HanAll Biopharma, Invirsa, IVIEW Therapeutics, Kowa Company, MC2 Therapeutics, Novaliq, Novaliq GmbH, Noveome, Ocular Therapeutix, Palatin Technologies, Quorum Innovations, Seikagaku Corporation, Seinda Pharmaceutical, Serentrix, Taejoon Pharmaceutical, and others
Key Dry Eye Disease Therapies: OTX-DED, HL036, PL9643, and others
Dry Eye Disease Therapeutic Assessment: Dry Eye Disease current marketed and Dry Eye Disease emerging therapies
Dry Eye Disease Market Dynamics: Dry Eye Disease market drivers and Dry Eye Disease market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Dry Eye Disease Unmet Needs, KOL’s views, Analyst’s views, Dry Eye Disease Market Access and Reimbursement
To know more about Dry Eye Disease companies working in the treatment market, visit @ Dry Eye Disease Therapeutic Assessment
Table of Contents
1. Dry Eye Disease Market Report Introduction
2. Executive Summary for Dry Eye Disease
3. SWOT analysis of Dry Eye Disease
4. Dry Eye Disease Patient Share (%) Overview at a Glance
5. Dry Eye Disease Market Overview at a Glance
6. Dry Eye Disease Disease Background and Overview
7. Dry Eye Disease Epidemiology and Patient Population
8. Country-Specific Patient Population of Dry Eye Disease
9. Dry Eye Disease Current Treatment and Medical Practices
10. Dry Eye Disease Unmet Needs
11. Dry Eye Disease Emerging Therapies
12. Dry Eye Disease Market Outlook
13. Country-Wise Dry Eye Disease Market Analysis (2020–2034)
14. Dry Eye Disease Market Access and Reimbursement of Therapies
15. Dry Eye Disease Market Drivers
16. Dry Eye Disease Market Barriers
17. Dry Eye Disease Appendix
18. Dry Eye Disease Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Related Reports:
Dry Eye Disease Pipeline
“Dry Eye Disease Pipeline Insight, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Dry Eye Disease market. A detailed picture of the Dry Eye Disease pipeline landscape is provided, which includes the disease overview and Dry Eye Disease treatment guidelines.
DelveInsight’s ‘Dry Eye Disease Epidemiology Forecast to 2034’ report delivers an in-depth understanding of the disease, historical and forecasted Dry Eye Disease epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kritika RehaniEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/
